169 related articles for article (PubMed ID: 26554886)
1. Update on biosimilars of granulocyte colony-stimulating factor - when no news is good news.
Schulz M; Bonig H
Curr Opin Hematol; 2016 Jan; 23(1):61-6. PubMed ID: 26554886
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
3. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.
Salesi N; Di Cocco B; Colonna M; Veltri E
Future Oncol; 2012 May; 8(5):625-30. PubMed ID: 22401144
[TBL] [Abstract][Full Text] [Related]
5. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
6. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Bonig H; Becker PS; Schwebig A; Turner M
Transfusion; 2015 Feb; 55(2):430-9. PubMed ID: 24965197
[TBL] [Abstract][Full Text] [Related]
9. Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
Krendyukov A; Schiestl M; Höbel N; Aapro M
Support Care Cancer; 2018 Jan; 26(1):33-40. PubMed ID: 28929372
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: the science of extrapolation.
Weise M; Kurki P; Wolff-Holz E; Bielsky MC; Schneider CK
Blood; 2014 Nov; 124(22):3191-6. PubMed ID: 25298038
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with Zarzio® in Europe: what have we learned?
Gascón P; Tesch H; Verpoort K; Rosati MS; Salesi N; Agrawal S; Wilking N; Barker H; Muenzberg M; Turner M
Support Care Cancer; 2013 Oct; 21(10):2925-32. PubMed ID: 23903799
[TBL] [Abstract][Full Text] [Related]
12. Commentary - A comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars and Intended Copy Biologics in treating chemotherapy associated febrile neutropenia.
Cornes PG; Muenzberg M
Toxicol Appl Pharmacol; 2020 Nov; 406():115202. PubMed ID: 32822736
[TBL] [Abstract][Full Text] [Related]
13. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in oncology: Effects on economy and therapeutic innovations.
Hübel K; Kron F; Lux MP
Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy.
Danova M; Pronzato P; Ingrasciotta Y; Antonuzzo A; Trama U; Tondini C; Bernardi FF
Future Oncol; 2020 May; 16(14):891-897. PubMed ID: 32329365
[TBL] [Abstract][Full Text] [Related]
16. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
17. Will biosimilars gain momentum?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2013 Oct; 11(10):1291-7. PubMed ID: 24142828
[TBL] [Abstract][Full Text] [Related]
18. Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
Barcina Lacosta T; Inotai A; Pereira CL; Barbier L; Simoens S
Value Health; 2024 May; 27(5):543-551. PubMed ID: 38702140
[TBL] [Abstract][Full Text] [Related]
19. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
20. Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator.
Tilleul PR; Rodgers-Gray BS; Edwards JO
J Oncol Pharm Pract; 2021 Oct; 27(7):1604-1615. PubMed ID: 33019875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
